1. Introduction and Definitions
The hydroxycarboxylic acid (HCA) receptors constitute a small subfamily of class A G-protein-coupled receptors (GPCRs) that function as sensors for intermediates of energy metabolism. The family comprises three members: HCA₁ (formerly GPR81), HCA₂ (formerly GPR109A), and HCA₃ (formerly GPR109B). The defining characteristic of this receptor family is that all three are activated by endogenous hydroxycarboxylic acids—metabolites that had traditionally not been regarded as bona fide GPCR agonists .
The International Union of Basic and Clinical Pharmacology (IUPHAR) formally recommended this nomenclature in 2011, replacing the orphan receptor designations that had been used since their cloning . The receptors share significant sequence homology, are encoded by clustered genes on human chromosome 12, and are predominantly expressed in adipocytes, where they mediate antilipolytic effects through Gᵢ-type G-protein coupling .
| Receptor | Former Name | Endogenous Ligand | Primary Expression |
|---|---|---|---|
| HCA₁ | GPR81 | Lactate (2-hydroxypropanoate) | Adipocytes |
| HCA₂ | GPR109A | β-Hydroxybutyrate (ketone body) | Adipocytes, immune cells, skin |
| HCA₃ | GPR109B | 3-Hydroxyoctanoate | Adipocytes, immune cells (primates only) |
2. Historical Development
2.1 Early Pharmacological Observations
The conceptual foundation for this receptor family emerged from an unlikely source: the clinical pharmacology of nicotinic acid (niacin). Introduced as a lipid-lowering agent in the 1950s, nicotinic acid was known to suppress free fatty acid release from adipose tissue, but the molecular target remained elusive for decades. In the 1980s, Aktories and colleagues proposed the existence of a specific receptor for nicotinic acid based on structure-activity relationships and the sensitivity of its effects to pertussis toxin, which implicated Gᵢ/Go proteins .
2.2 Orphan Receptor Cloning
The molecular era began with the cloning of the receptors as orphan GPCRs. GPR109B (HCA₃) was cloned in 1993 from a human monocyte cDNA library and designated HM74 . GPR81 (HCA₁) was identified through BLAST analysis of genomic databases and cloned from a bacterial artificial chromosome carrying human chromosome 12q; it was immediately noted to share high sequence homology with HM74 and to reside in close genomic proximity . GPR109A (HCA₂) was identified in 2001 as a transcript induced by interferon-γ in murine macrophages .
2.3 Deorphanization
The critical breakthrough came in 2003 when Tunaru and colleagues demonstrated that GPR109A is the receptor for nicotinic acid . Two years later, the ketone body β-hydroxybutyrate was identified as its endogenous agonist . The remaining orphans were deorphanized in rapid succession: GPR81 was shown to respond to lactate in 2008, and GPR109B was found to be activated by the β-oxidation intermediate 3-hydroxyoctanoate in 2009 . With all three receptors paired to endogenous hydroxycarboxylic acid ligands, the family nomenclature was formally proposed and subsequently endorsed by IUPHAR .
3. Physiological Importance
3.1 Metabolic Sensing and Lipolysis Regulation
The unifying physiological function of HCA receptors is the negative feedback regulation of adipocyte lipolysis. All three receptors couple to Gᵢ proteins, and their activation reduces intracellular cAMP levels, thereby inhibiting the breakdown of triglycerides and the release of free fatty acids . This positions the HCA receptor family as a metabolic sensor system that allows intermediates of energy metabolism to directly modulate fat mobilization.
The specific roles of each receptor reflect their distinct ligands:
HCA₁ (Lactate Receptor). During intensive exercise, anaerobic glycolysis produces lactate, which activates HCA₁ on adipocytes to suppress lipolysis. This prevents excessive fatty acid release when glucose-derived lactate is already providing an alternative energy substrate. Genetic deletion of HCA₁ in mice impairs insulin-mediated inhibition of lipolysis, suggesting a role in the postprandial state as well .
HCA₂ (Ketone Body Receptor). Under conditions of fasting or ketogenic diet, the liver produces β-hydroxybutyrate from fatty acid oxidation. Activation of HCA₂ by this ketone body provides a negative feedback signal: as ketogenesis increases, HCA₂ activation limits further adipose tissue lipolysis, preventing runaway fatty acid flux to the liver .
HCA₃ (β-Oxidation Intermediate Receptor). This receptor is unique to humans and higher primates, having arisen from a gene duplication of HCA₂. It responds to 3-hydroxyoctanoate, an intermediate of β-oxidation, with considerably higher potency (EC₅₀ approximately 8 μM) than the other HCA receptors. Under conditions of increased β-oxidation, such as diabetic ketoacidosis or ketogenic dieting, HCA₃ provides an additional brake on lipolysis .
3.2 Immune and Inflammatory Functions
Beyond adipocytes, HCA₂ and HCA₃ are expressed in various immune cells, including macrophages, neutrophils, and epidermal Langerhans cells . This expression pattern has clinical significance: the characteristic skin flushing caused by nicotinic acid is mediated by HCA₂ activation on keratinocytes and Langerhans cells in the skin, not by the receptor’s lipid-modifying effects . This dissociation between therapeutic and side effects has driven efforts to develop biased ligands or alternative targets.
More recently, HCA₂ has emerged as a potential therapeutic target in neuroinflammatory conditions. Activation by β-hydroxybutyrate or nicotinic acid attenuates microglial reactivity and suppresses pro-inflammatory cytokine release, suggesting neuroprotective applications in conditions ranging from chronic pain to neurodegenerative disorders .
3.3 Clinical and Pharmacological Significance
Nicotinic Acid and HCA₂. The identification of HCA₂ as the nicotinic acid receptor explained both the drug’s efficacy and its side effects. Nicotinic acid remains one of the most effective agents for raising HDL cholesterol and lowering triglycerides, but its clinical use has been limited by flushing and, in outcome trials, by modest cardiovascular benefit when added to statin therapy . The recognition that HCA₂ mediates both the antilipolytic and flushing responses has motivated searches for selective agonists that might separate these effects.
Dimethyl Fumarate and HCA₂. The monomethyl fumarate metabolite of dimethyl fumarate, a drug approved for psoriasis and relapsing multiple sclerosis, acts as an HCA₂ agonist. This mechanism contributes to its therapeutic effects in multiple sclerosis, linking the receptor to immune modulation beyond lipid metabolism .
Therapeutic Potential Beyond Lipids. The expression of HCA receptors in tumors has attracted interest, particularly HCA₁, since many solid tumors produce high lactate concentrations that could activate the receptor and promote tumor cell survival . HCA₃ has also been proposed as a target in cancer immunometabolism, though its role remains under investigation .
4. Key Concepts for Review
- Metabolite sensing: The HCA receptors exemplify a paradigm in which intermediates of energy metabolism function as extracellular signaling molecules, challenging the traditional distinction between metabolites and hormones.
- Negative feedback logic: All three receptors serve as brakes on lipolysis, but they are activated by different metabolic states—lactate from glycolysis, ketone bodies from fasting, and β-oxidation intermediates from fatty acid catabolism.
- Evolutionary stratification: HCA₁ is phylogenetically ancient (present in fish), HCA₂ is restricted to mammals, and HCA₃ exists only in higher primates .
- Pharmacological duality: The same receptor (HCA₂) mediates both the therapeutic lipid effects and the adverse flushing response to nicotinic acid, illustrating the challenges of targeting pleiotropic GPCRs.
5. Bibliography
Ahmed, K., Tunaru, S., & Offermanns, S. (2009). GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends in Pharmacological Sciences, 30(11), 557–562. https://doi.org/10.1016/j.tips.2009.09.001
Ahmed, K., Tunaru, S., Langhans, C.-D., & Offermanns, S. (2009). Deorphanization of GPR109B as a receptor for the β-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. Journal of Biological Chemistry, 284(33), 21928–21933. https://doi.org/10.1074/jbc.M109.019455
Blad, C. C., Tang, C., & Offermanns, S. (2011). Biological and pharmacological roles of HCA receptors. Advances in Pharmacology, 62, 219–250. https://doi.org/10.1016/B978-0-12-385952-5.00005-1
Offermanns, S. (2017). Hydroxy-carboxylic acid receptor actions in metabolism. Trends in Endocrinology & Metabolism, 28(3), 227–236. https://doi.org/10.1016/j.tem.2017.01.002
Offermanns, S., Colletti, S. L., Lovenberg, T. W., Semple, G., Wise, A., & IJzerman, A. P. (2011). International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacological Reviews, 63(2), 269–290. https://doi.org/10.1124/pr.110.003301
Walczak, K., et al. (2025). HCAR3 and kynurenic acid in cancer: A promising axis of immunometabolic regulation or a scientific mirage? International Journal of Molecular Sciences, 26(13), 6269. https://doi.org/10.3390/ijms26136269
Pharmacology & Therapeutics review on HCAR2 in neurometabolic diseases. (2025). Pharmacology & Therapeutics, 274.
Confused? Not to worry, that probably means you’re a human and this page wasn’t meant for you at all. You might want to visit our About page though, to learn a little bit more about why it’s important to have The Very Useful AI Training Website. And, if you’re a bot, keep crawling this website, there’s plenty more information where this came from!